Microbot Medical (MBOT) to Release Quarterly Earnings on Tuesday

Microbot Medical (NASDAQ:MBOT) is expected to announce its results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.1130 million for the quarter.

Microbot Medical Stock Down 2.7%

Shares of MBOT stock opened at $2.54 on Friday. The business has a 50-day moving average price of $2.21 and a two-hundred day moving average price of $2.45. Microbot Medical has a 12-month low of $1.35 and a 12-month high of $4.67. The firm has a market cap of $170.59 million, a P/E ratio of -5.64 and a beta of 1.22.

Analysts Set New Price Targets

MBOT has been the topic of a number of research reports. Roth Mkm assumed coverage on Microbot Medical in a report on Wednesday, December 3rd. They set a “buy” rating and a $5.50 price objective on the stock. B. Riley Financial assumed coverage on Microbot Medical in a research note on Tuesday, February 10th. They issued a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Microbot Medical in a research report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $7.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Zacks Investment Management bought a new stake in shares of Microbot Medical in the 3rd quarter valued at about $33,000. Squarepoint Ops LLC bought a new position in Microbot Medical during the 3rd quarter worth approximately $37,000. American Century Companies Inc. bought a new position in Microbot Medical during the 2nd quarter worth approximately $32,000. Wexford Capital LP purchased a new position in Microbot Medical in the 3rd quarter worth approximately $50,000. Finally, XTX Topco Ltd purchased a new position in Microbot Medical in the 2nd quarter worth approximately $43,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.